DFTX (Definium Therapeutics) Moat Score: 3/10 (As of Jun. 30, 2026)


DFTX Definium Therapeutics Inc DFTX
32 GF Score
Price $47.04
! 5 Warning Signs
View Full Analysis

What is Definium Therapeutics Moat Score?

Definium Therapeutics DFTX +1.07% 32 Moat Score is 3 as of Jun. 30, 2026. GuruFocus rates DFTX with a GF Score™ of 32/100. The stock has 5 warning signs investors should review. Among 1,401 Biotechnology companies, Definium Therapeutics ranks better than 75.52% on this metric.

Definium Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Definium Therapeutics has No Moat: Definium Therapeutics Inc has limited market share and lacks significant intellectual property or regulatory barriers. The company does not demonstrate strong brand strength or customer loyalty, and its innovation capabilities are not yet impactful.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Definium Therapeutics might have No Moat - Very weak/transient advantages.

Definium Therapeutics  (NAS:DFTX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Definium Therapeutics Moat Score Related Terms

DFTX vs LGND, XENE, CGON: Moat Score Comparison

For the Biotechnology subindustry, Definium Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Definium Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Definium Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Definium Therapeutics's Moat Score falls into.


DFTX
32GF Score
Definium Therapeutics Inc DFTX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Definium Therapeutics (DFTX) has a Moat Score of 3 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Definium Therapeutics ranks #343 out of 1401 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Definium Therapeutics' Moat Score too high?
Definium Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Definium Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Definium Therapeutics ranks #343 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Definium Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Definium Therapeutics' Moat Score compare to LGND and XENE?
According to the Biotechnology industry distribution chart, Definium Therapeutics ranks #343 out of 1401 companies for Moat Score. This places Definium Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Definium Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Definium Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Definium Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Definium Therapeutics stock overvalued right now?
Definium Therapeutics (DFTX) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Definium Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Definium Therapeutics (DFTX), the current Moat Score is 3 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Definium Therapeutics Business Description

Other Exchanges MMQ0:Germany
Address One World Trade Center, Suite 8500, New York, NY, USA, 10007
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
32GF Score

Get the complete analysis for DFTX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.04
Price